user
menu
letter
Sign InRegister
langEnglisharrow

LAG-3

LAG-3

LAG-3 Overview

Molecule Name
Lymphocyte activation gene 3 protein
Synonyms
LAG3,CD223,FDC
Drug Development Progress
Drugs in Clinical Trials31
Approved Drugs1
Highest Development StageApproved
Target Synonym
Lymphocyte activation gene 3 protein，LAG3，Lymphocyte Activating 3，Lymphocyte-Activation Gene 3，CD223 Antigen，Protein FDC，CD223，LAG-3，FDC，sLAG-3
Background
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

LAG-3 Product List

Species
  • Human（9）
  • Cynomolgus（5）
  • Mouse（4）
  • Canine（1）
  • Rat（1）
Tag
  • His Tag（7）
  • Fc Tag（3）
  • His Tag & Avi Tag（3）
  • Mouse IgG Fc Tag（3）
  • Fc Tag & Avi Tag（2）
  • Llama IgG Fc Tag（1）
  • Mouse IgG Fc Tag & Avi Tag（1）
Host
  • HEK293（20）
Conjugate
  • Unconjugated（12）
  • Biotin-labeled（7）
  • PE Labeled（1）
Grade
  • RUO（20）
Low Endotoxin
  • Yes（6）
  • No（14）
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
LAG-3
HOT
LA3-H5255
Human LAG3 / CD223 Protein, Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLI

$340.00

100ug
LAG-3
HOT
LA3-H5222
Human LAG-3 / CD223 Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLI

$370.00

100ug
LAG-3
HOT
LA3-M52H5
Mouse LAG-3 / CD223 Protein, His Tag, low endotoxin (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
LAG-3
HOTAvitag
LA3-H82E9
Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
LAG-3
HOTAvitag
LA3-H82F3
Biotinylated Human LAG-3 / CD223 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$360.00

25ug
LAG-3
LA3-C5252
Cynomolgus LAG-3 / CD223 Protein, Fc Tag, low endotoxin (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISAFlow

$360.00

100ug
LAG-3
LA3-C52A0
Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag (HPLC verified)
Cynomolgus
HEK293
HPLCSDS-PAGE
ELISA

$420.00

100ug
LAG-3
LA3-C52H7
Canine LAG-3 / CD223 Protein, His Tag (MALS verified)
Canine
HEK293
MALSSDS-PAGE

$360.00

100ug
LAG-3
LA3-C8258
Biotinylated Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, ultra sensitivity (primary amine labeling) (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
LAG-3
Avitag
LA3-C82E5
Biotinylated Cynomolgus LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
You Have Viewed 1-10 Of 20 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Product InquiryRequest Customization
FAQ

Can recombinant LAG-3 proteins support monospecific and bispecific antibody development?

Yes. Recombinant LAG-3 proteins can support direct antibody-binding and multi-target assay configurations when an appropriate protein format is selected. Human LAG-3 Protein, His Tag (Cat. No. LA3-H5222), for example, has been evaluated for anti-LAG-3 antibody binding by ELISA, SPR, and BLI and has also been used in ELISA-based assays involving the LAG-3 × PD-1 bispecific antibody tebotelimab. These results demonstrate specific assay configurations and should not be interpreted as validation of every LAG-3 protein for the same applications.

What validation data should I consider when selecting a recombinant LAG-3 protein?

Relevant validation may include protein purity and molecular characterization together with ligand- or antibody-binding measurements appropriate to the intended assay. Selected ACROBiosystems LAG-3 proteins include SEC-MALS and bioactivity data generated using methods such as ELISA, SPR, and BLI. Because these results are generated for individual products under defined conditions, the validation package for the specific catalog number should be reviewed before selection.

Which LAG-3 protein species are suitable for human and preclinical studies?

Species selection should correspond to the therapeutic target and biological model being evaluated. ACROBiosystems provides recombinant LAG-3 proteins from human, cynomolgus, mouse, rat, and canine sources, enabling studies across human-target and relevant preclinical systems. For cross-species comparisons, researchers should also consider differences in construct and tag format when interpreting binding data.

How do His, Fc, biotinylated, and untagged LAG-3 proteins fit different assay designs?

Protein format should be matched to the assay's capture, immobilization, and detection strategy. ACROBiosystems provides His- and Fc-tagged LAG-3 proteins, site-specifically biotinylated Avi-tag formats, and untagged products for applications where an additional fusion tag is not desired. PE-labeled human LAG-3 is also available for compatible fluorescence-based assays, and product-specific validation should be reviewed when selecting a format.

How should I select a LAG-3 protein for studying LAG-3–FGL1 interactions?

Protein selection should consider species, construct, tag configuration, and the intended binding assay. Selected ACROBiosystems LAG-3 proteins have product-specific FGL1-binding data; for example, Human LAG-3 Protein, Fc Tag (Cat. No. LA3-H5255) has been evaluated for binding to human FGL1 by BLI. These results apply to the tested product and assay conditions and should not be generalized to all LAG-3 protein formats.

What types of assays can recombinant LAG-3 proteins support?

Recombinant LAG-3 proteins can support ligand-binding studies, antibody screening, affinity characterization, and assay development for LAG-3-targeting therapeutics. ACROBiosystems provides LAG-3 proteins in multiple species, tag configurations, and labeling formats to accommodate different assay designs. The appropriate reagent should be selected according to the interaction being measured and the planned immobilization or detection strategy.
Asset Licensing Opportunity

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
LAG-3 mAbMonospecific antibodyOncology/CancerAdvanced solid tumorPhase IGlobal
Project Name
LAG-3 mAb
Drug Type
Monospecific antibody
Therapeutic Area
Oncology/Cancer
Indication
Advanced solid tumor
Stage
Phase I
Rights Area
Global
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
RelatlimabONO-4482; BMS-986016Phase 3 ClinicalBristol-Myers Squibb Company
Adenocarcinoma; Brain metastases; Brain Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Glioblastoma; Gliosarcoma; Hematologic Neoplasms; Hodgkin Disease; Large intestine neoplasm; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male Urogenital Diseases; Melanoma; Microsatellite instability-high cancer; Multiple Myeloma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms; Uveal melanoma
Details
FianlimabREGN-3767Phase 3 ClinicalRegeneron Pharmaceuticals Inc
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms
Details
TebotelimabPD-1 X LAG-3; MGD-013Phase 3 ClinicalMacrogenics Inc
Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
Mavezelimab/PembrolizumabMK-4280A; MK-4820APhase 3 ClinicalMerck Sharp & Dohme Corp
Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours
Details
SHR-1802SHR-1802Phase 2 ClinicalJiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd
Neoplasms; Solid tumours
Details
TobemstomigRO-7247669Phase 2 ClinicalF. Hoffmann-La Roche Ltd
Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Liver Neoplasms; Melanoma; Solid tumours
Details
AlcestobartLBL-007Phase 2 ClinicalLeads Biolabs Inc
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Lymphoma; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
NegalstobartIBI-110Phase 2 Clinical
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Neoplasms; Skin Melanoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck
Details
MavezelimabMK-4280Phase 2 ClinicalMerck Sharp & Dohme Corp
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Small Cell Lung Carcinoma
Details
IeramilimabIMP-701; LAG-525Phase 2 ClinicalImmutep
Esophageal adenocarcinoma; Lymphoma, Large B-Cell, Diffuse; Melanoma; Ovarian Neoplasms; Persistent Fetal Circulation Syndrome; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
MiptenalimabBI-754111Phase 2 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours
Details
AK-129AK-129Phase 2 Clinical
Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
HLX-26HLX-26Phase 2 Clinical
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lymphoma; Solid tumours
Details
GLS-012GLS-012Phase 2 ClinicalHarbin Gloria Pharmaceuticals Co Ltd
Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours
Details
EMB-02EMB-02Phase 2 ClinicalShanghai Epimab Biotherapeutics, Inc
Solid tumours
Details
DNV-3DNV-3; DNV3Phase 2 ClinicalZhejiang Shimai Pharmaceutical Co Ltd
Lymphoma; Melanoma; Neoplasms; Skin Neoplasms; Solid tumours
Details
KL-A289KL-A289Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Solid tumours
Details
BavunalimabXmAb-22841; XmAb-841Phase 1 ClinicalXencor Inc
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Penile Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
IMP-761IMP-761Phase 1 ClinicalImmutep
Autoimmune Diseases
Details
Sym-022Sym-022; Sym022; S95017Phase 1 ClinicalSymphogen A/S
Lymphoma; Neoplasm Metastasis; Solid tumours
Details
MIL-98MIL-98Phase 1 ClinicalBeijing Mabworks Biotech Co Ltd
Breast Neoplasms; Lymphoma; Melanoma; Solid tumours
Details
AN-8025AN-8025Phase 1 ClinicalHangzhou Adlai Nortye Biopharma Co Ltd
Solid tumours
Details
ABL-501ABL-501Phase 1 ClinicalAbl Bio Inc
Solid tumours
Details
TQB-2252TQB-2252; TQB2252Phase 1 ClinicalChia Tai Tianqing (Guangzhou) Pharmaceutical Co Ltd
Neoplasms; Solid tumours
Details
AK-137AK137; AK-137Phase 1 Clinical
Neoplasms
Details
SSGJ-709SSGJ-709; SSGJ709Phase 1 ClinicalShenyang Sunshine Pharmaceutical Co Ltd
Neoplasms; Solid tumours
Details
JY-03JY03; JY-03Phase 1 ClinicalBeijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd
Solid tumours
Details
ZGGS-15ZGGS15; ZGGS-15Phase 1 ClinicalSuzhou Zelgen Biopharmaceuticals Co Ltd
Solid tumours
Details
IBI-323(Innovent Biologics)IBI-323Phase 1 Clinical
Neoplasms; Solid tumours
Details
EncelimabTSR-033; TSR 033; TSR033; GSK-4074386Phase 1 ClinicalAnaptysbio Inc
Neoplasms
Details
68Ga-DOTA-hLAG-3ClinicalThe First Affiliated Hospital Of Xiamen University
Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Nivolumab/RelatlimabBMS-986213; BMS-936558/BMS-986016ApprovedBristol-Myers Squibb CompanyOPDUALAGUnited StatesMelanomaBristol-Myers Squibb Company2022-03-18
Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Skin Melanoma; Solid tumours; Stomach Neoplasms
Details
Customer Reviews
  • N***r2022-11-08
    Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
    Ordered this reagent for a binding ELISA performed for a client. Client had questions about extending the reagent expiry and getting extra documentation provided for a GMP project. Acros customer service was great in answering all of my questions and providing documentation within just a few mins. I was provided with the COA and a memo ensuring the expiry could be extended from data that Acros had collected. I was also able to talk to other scientists on the technical side of their customer services and ensure that what I was relaying to the client was accurate. Really helped out on this project and the client was very happy! Thank you Acros!
  • 1***12019-11-07
    Human LAG-3 / CD223 Protein, His Tag, low endotoxin (MALS verified)
    I purchased Acro's protein many times for experiments. LAG3 was used mostly, and the titer after immunization can reach more than 100,000. It is a very good product.
  • 1***92019-10-11
    Human LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
    We purchased ACRO's Human LAG3-mFc protein, and we tested its affinity with the antibody on Biacore T200. The results showed that the affinity was within the normal range, and the protein bioactivity is very good!
  • 1***62019-10-11
    Human LAG-3 / CD223 Protein, His Tag, low endotoxin (MALS verified)
    The protein was purchased for my study. It has good purity, which ensured that we obtained high-value antiserum in the animal immunization experiments. We performed multiple batches of immunization. They were stable and had good immune effect.
  • 1***22019-09-26
    Human LAG-3 / CD223 Protein, His Tag, low endotoxin (MALS verified)
    I used this protein as an immune antigen in antibody development project. We obtained a pretty high serum titer. We purchased several batches of the protein, and performed multiple experiments. It proved that there was basically no difference among the batches.